Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea
Purpose: In this study, we aimed to retrospectively investigate the real-world clinical efficacy and adverse events of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in real-world clinical practice among patients with newly diagnosed epithelial ovarian cancer. Methods: We retr...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/11/495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850145187384262656 |
|---|---|
| author | Hyeong In Ha Hyung Joon Yoon Changho Song Eun Taeg Kim Dong-Soo Suh Ki Hyung Kim Yong Jin Na Yong Jung Song |
| author_facet | Hyeong In Ha Hyung Joon Yoon Changho Song Eun Taeg Kim Dong-Soo Suh Ki Hyung Kim Yong Jin Na Yong Jung Song |
| author_sort | Hyeong In Ha |
| collection | DOAJ |
| description | Purpose: In this study, we aimed to retrospectively investigate the real-world clinical efficacy and adverse events of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in real-world clinical practice among patients with newly diagnosed epithelial ovarian cancer. Methods: We retrospectively reviewed the medical records from hospitals. Patients with epithelial ovarian cancer treated with olaparib or niraparib as frontline maintenance treatment between 1 January 2014 and 31 December 2022 were included. Progression-free survival (PFS) was analyzed using the Kaplan–Meier method, and adverse events associated with PARP inhibitor treatment were investigated. Results: Ninety-six patients treated with PARP inhibitors were identified. The median follow-up period was 21.8 months (95% confidence interval [CI] 19.4–24.0). Twenty (20.1%) patients experienced disease progression, and two patients died. The median PFS was 45.3 months (95% CI 39.4–NA). <i>BRCA1</i> or <i>BRCA2</i> gene mutations and primary cytoreductive surgery were associated with better PFS. Adverse events of any grade occurred in 74 (77.1%) patients. Nineteen (19.8%) patients experienced PARP inhibitor therapy interruptions, and 35 (36.5%) patients experienced dose reductions. Only three patients discontinued the drug due to adverse events. Conclusions: In a real-world setting, PARP inhibitors showed efficacy comparable to that reported in published randomized controlled trials and had acceptable safety profiles. |
| format | Article |
| id | doaj-art-5ce1ebf81db444ce873ff71f9a0433f7 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-5ce1ebf81db444ce873ff71f9a0433f72025-08-20T02:28:09ZengMDPI AGCurrent Oncology1198-00521718-77292024-10-0131116711672210.3390/curroncol31110495Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of KoreaHyeong In Ha0Hyung Joon Yoon1Changho Song2Eun Taeg Kim3Dong-Soo Suh4Ki Hyung Kim5Yong Jin Na6Yong Jung Song7Department of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of KoreaDepartment of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of KoreaDepartment of Obstetrics and Gynecology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Republic of KoreaDepartment of Obstetrics and Gynecology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49267, Republic of KoreaDepartment of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of KoreaDepartment of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of KoreaDepartment of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of KoreaDepartment of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of KoreaPurpose: In this study, we aimed to retrospectively investigate the real-world clinical efficacy and adverse events of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in real-world clinical practice among patients with newly diagnosed epithelial ovarian cancer. Methods: We retrospectively reviewed the medical records from hospitals. Patients with epithelial ovarian cancer treated with olaparib or niraparib as frontline maintenance treatment between 1 January 2014 and 31 December 2022 were included. Progression-free survival (PFS) was analyzed using the Kaplan–Meier method, and adverse events associated with PARP inhibitor treatment were investigated. Results: Ninety-six patients treated with PARP inhibitors were identified. The median follow-up period was 21.8 months (95% confidence interval [CI] 19.4–24.0). Twenty (20.1%) patients experienced disease progression, and two patients died. The median PFS was 45.3 months (95% CI 39.4–NA). <i>BRCA1</i> or <i>BRCA2</i> gene mutations and primary cytoreductive surgery were associated with better PFS. Adverse events of any grade occurred in 74 (77.1%) patients. Nineteen (19.8%) patients experienced PARP inhibitor therapy interruptions, and 35 (36.5%) patients experienced dose reductions. Only three patients discontinued the drug due to adverse events. Conclusions: In a real-world setting, PARP inhibitors showed efficacy comparable to that reported in published randomized controlled trials and had acceptable safety profiles.https://www.mdpi.com/1718-7729/31/11/495ovarian cancerPARP inhibitor |
| spellingShingle | Hyeong In Ha Hyung Joon Yoon Changho Song Eun Taeg Kim Dong-Soo Suh Ki Hyung Kim Yong Jin Na Yong Jung Song Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea Current Oncology ovarian cancer PARP inhibitor |
| title | Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea |
| title_full | Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea |
| title_fullStr | Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea |
| title_full_unstemmed | Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea |
| title_short | Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea |
| title_sort | clinical outcomes of poly adp ribose polymerase inhibitors as maintenance therapy in patients with ovarian cancer in the southeastern region of korea |
| topic | ovarian cancer PARP inhibitor |
| url | https://www.mdpi.com/1718-7729/31/11/495 |
| work_keys_str_mv | AT hyeonginha clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT hyungjoonyoon clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT changhosong clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT euntaegkim clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT dongsoosuh clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT kihyungkim clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT yongjinna clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea AT yongjungsong clinicaloutcomesofpolyadpribosepolymeraseinhibitorsasmaintenancetherapyinpatientswithovariancancerinthesoutheasternregionofkorea |